Condition
B Cell ALL
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06799221Unknown
Expanded Access Program for OOS Obe-cel
NCT04148430Phase 2Active Not RecruitingPrimary
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
NCT06777264Phase 2Not Yet Recruiting
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1
Showing all 3 trials